Company intelligence / Profile preview

Tcelltech GmbH

Mannheim, Baden-Württemberg, Germanytcelltech.eu ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Tcelltech GmbH is developing UNIPACT, a universal personalized adoptive cell therapy platform that rapidly identifies and engineers patient-specific tumor-reactive T cells using proprietary AI-driven discovery and non-integrating gene delivery technology. The approach aims to overcome current immunotherapy limitations by enabling fast production timelines suitable even for aggressive tumors and improving safety/efficacy over existing therapies. No published clinical data yet.

Therapeutic areas: Oncology
Modalities: Adoptive cell therapyGenetically engineered T cells (TCR-T)Non-viral gene delivery vectors
Industry: Biotech

Drug pipeline

4 assets

DIT101

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tcelltech GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tcelltech GmbH.

Explore the full profile